Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 37 of the 40 references it cites were found in a registry or an index.

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Abstract

Background Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel in patients with relapsed or refractory large B-cell lymphomas. Methods We did a seamless design study at 14 cancer centres in the USA. We enrolled adult patients (aged ≥18 years) with relapsed or refractory large B-cell lymphomas. Eligible histological subgroups included diffuse large B-cell lymphoma, high-grade B-cell lymphoma with rearrangements of MYC and either BCL2, BCL6, or both (double-hit or triple-hit lymphoma), diffuse large B-cell lymphoma transformed from any indolent lymphoma, primary mediastinal B-cell lymphoma, and follicular lymphoma grade 3B. Patients were assigned to one of three target dose levels of liso-cel as they were sequentially tested in the trial (50 × 10 6 CAR + T cells [one or two doses], 100 × 10 6 CAR + T cells, and 150 × 10 6 CAR + T cells), which were administered as a sequential infusion of two components (CD8 + and CD4 + CAR + T cells) at equal target doses. Primary endpoints were adverse events, dose-limiting toxicities, and the objective response rate (assessed per Lugano criteria); endpoints were assessed by an independent review committee in the efficacy-evaluable set (comprising all patients who had confirmed PET-positive disease and received at least one dose of liso-cel). This trial is registered with ClinicalTrials.gov, NCT02631044. Findings Between Jan…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)31366-0

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. DeAngelo, 2017, Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET study), J Immunother Cancer, 5, 116

Cited by

See all 2,430

Metadata

Authors
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., Solomon, S. R., Ghosh, N., Albertson, T. M., Garcia, J., Kostic, A., Mallaney, M., Ogasawara, K., Newhall, K., Kim, Y., Li, D., & Siddiqi, T.
Affiliations
  • Massachusetts General Hospital (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Northwestern University (US)
  • University of Nebraska Medical Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Beth Israel Deaconess Medical Center (US)
  • University of Alabama at Birmingham (US)
  • University of Colorado Anschutz (US)
  • Fred Hutch Cancer Center (US)
  • University of California, San Francisco (US)
  • UPMC Hillman Cancer Center (US)
  • Northside Hospital (US)
  • Levine Cancer Institute (US)
  • Bristol-Myers Squibb (United States) (US)
  • City Of Hope National Medical Center (US)
Corresponding author
Abramson, Jeremy S
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-09
Volume
396
Issue
10254
Pages
839-852
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3082855561
Cited by
2,430
References
40
Citations by year
2026: 299 · 2025: 419 · 2024: 481 · 2023: 444 · 2022: 479 · 2021: 288 · 2020: 16
FWCI
110.80
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Funders
Bristol-Myers Squibb
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
lisocabtagene maraleucel, CAR T-cell therapy, large B-cell lymphoma, relapsed/refractory lymphoma, CD19, diffuse large B-cell lymphoma, double-hit lymphoma, triple-hit lymphoma, primary mediastinal B-cell lymphoma, objective response rate, dose-limiting toxicity, neurotoxicity
MeSH terms
Cytokine Release Syndrome, Aged, Aged, 80 and over, Anemia, Biological Products, Female, Humans, Infusions, Intravenous, Leukapheresis, Male, Nervous System Diseases, Neutropenia, Recurrence, Safety, Thrombocytopenia, CD4-Positive T-Lymphocytes, Survival Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Treatment Outcome, CD8-Positive T-Lymphocytes, Antigens, CD19

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. https://app.cochat.ai/papers/10.1016/s0140-6736(20)31366-0
The paper
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., Solomon, S. R., Ghosh, N., Albertson, T. M., Garcia, J., Kostic, A., Mallaney, M., Ogasawara, K., Newhall, K., . . . Siddiqi, T. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. The Lancet. https://doi.org/10.1016/s0140-6736(20)31366-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.